CDH17 and prostate cancer: Among non-GI non-squamous pulmonary metastases, described in Supplementary Table 2, the highest frequency for the markers was seen for CDX2 in gynecological cancers (41%; 7/17) and prostatic cancer (36%; 4/11), followed by CDH17 in gynecological cancers (24%; 4/17).